Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.080
-0.020 (-1.82%)
At close: Dec 5, 2025, 4:00 PM EST
1.071
-0.009 (-0.81%)
After-hours: Dec 5, 2025, 7:40 PM EST
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
181
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$39,431
Profits / Employee
-$862,398
Market Cap
124.58M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FATE News
- 11 days ago - Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 23 days ago - Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - GlobeNewsWire
- 4 months ago - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 6 months ago - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - GlobeNewsWire
- 6 months ago - Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewsWire
- 6 months ago - Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewsWire